A phase‐II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71605 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Christopher R Martens und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology & Applied Physiology, University of Delaware, Newark, Delaware, USA. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Niacinamide, Dietary Supplements, Amnesia. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, National Institute on Aging.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
INTRODUCTION Declining nicotinamide adenine dinucleotide (NAD + ) may elevate risk of Alzheimer's disease. METHODS We conducted a 12‐week double‐blind, randomized, placebo‐controlled pilot study to evaluate the safety, tolerability, and preliminary efficacy of the NAD + precursor, nicotinamide riboside (NR), for enhancing cognitive function and cerebral blood flow (CBF) in adults with amnestic mild cognitive impairment (aMCI). RESULTS 42 participants completed the study (NR = 22, placebo = 20). Adherence was similar between groups with no serious adverse effects. Blood NAD + increased twofold in the NR group. There were no improvements in cognitive function (primary outcome), total CBF, or blood pressure (secondary outcomes). Exploratory analyses revealed potential increases in regional CBF, particularly in the hippocampus. DISCUSSION NR effectively raises NAD + in people with MCI but does not improve cognitive function, total CBF, or blood pressure over 12 weeks. Future studies should investigate regional effects on CBF over longer treatment durations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Kinesiology & Applied Physiology, University of Delaware, Newark, Delaware, USA.
- Delaware Center for Cognitive Aging Research, University of Delaware, Newark, Delaware, USA.
- Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Biomedical Engineering, University of Delaware, Newark, Delaware, USA.
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.
- Department of Epidemiology, University of Delaware, Newark, Delaware, USA.
ORCID-Profile: Christopher R Martens
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- National Institute on Aging
- National Institute of General Medical Sciences
Zitieren
APA
Martens, C. R., Decker, K. P., DeConne, T. M., Sanjana, F., Horvat, F., Rizzi, N. A., Awad, C., Habash, E., Hobson, J. C., Kramer, M. K., Armstrong, M. L., Reisdorph, N., Pohlig, R. T., Lanzi, A. M., Johnson, C. L., Cohen, M. L., & Ellison, J. M. (2026). A phase‐II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71605
Vancouver
Martens CR, Decker KP, DeConne TM, Sanjana F, Horvat F, Rizzi NA, et al. A phase‐II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71605
BibTeX
@article{Martens2026,
author = {Martens, Christopher R and Decker, Kevin P and DeConne, Theodore M and Sanjana, Faria and Horvat, Fiona and Rizzi, Nicholas A and Awad, Catherine and Habash, Elizabeth and Hobson, Joshua C and Kramer, Mary K and Armstrong, Michael L and Reisdorph, Nichole and Pohlig, Ryan T and Lanzi, Alyssa M and Johnson, Curtis L and Cohen, Matthew L and Ellison, James M},
title = {A phase‐II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71605}
}
EUVIMED